| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050834993 |
| P356 | DOI | 10.1007/S12016-015-8505-8 |
| P698 | PubMed publication ID | 26445774 |
| P50 | author | Margarida Lima | Q43234321 |
| Isabel Almeida | Q55743203 | ||
| Carlos Vasconcelos | Q56750258 | ||
| P2093 | author name string | Ivone Silva | |
| Ana Raquel Fonseca | |||
| Sara Vieira Silva | |||
| P2860 | cites work | Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy | Q71177273 |
| Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis | Q71574576 | ||
| Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture | Q72390200 | ||
| A disease severity scale for systemic sclerosis: development and testing | Q73101147 | ||
| Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis | Q73152856 | ||
| Increased interleukin-17 production in patients with systemic sclerosis | Q73202422 | ||
| Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis | Q73342255 | ||
| Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma | Q73661518 | ||
| Analysis of lymphocyte subpopulations in systemic sclerosis | Q73929175 | ||
| Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis | Q77872996 | ||
| Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment | Q77929352 | ||
| Is scleroderma an autoantibody mediated disease? | Q79279468 | ||
| Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? | Q80842225 | ||
| B cell infiltration in systemic sclerosis-associated interstitial lung disease | Q80974173 | ||
| Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis | Q81377104 | ||
| Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis | Q82810358 | ||
| A contemporary update on scleroderma | Q83367275 | ||
| Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts | Q83611830 | ||
| CD8+ T cells in systemic sclerosis | Q84474506 | ||
| Cytokines in acute and chronic inflammation | Q28645928 | ||
| The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes | Q33470222 | ||
| Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression | Q33471458 | ||
| Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies | Q33563659 | ||
| Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity | Q33567347 | ||
| Assessing microvascular changes in systemic sclerosis diagnosis and management | Q33655176 | ||
| Comparison of serum and cell-specific cytokines in humans | Q33999709 | ||
| Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis | Q34287872 | ||
| Criteria for the classification of early systemic sclerosis. | Q34317138 | ||
| International consensus criteria for the diagnosis of Raynaud's phenomenon | Q34401929 | ||
| The biology of human natural killer-cell subsets | Q34430869 | ||
| Diagnostic criteria of systemic sclerosis | Q34659218 | ||
| Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. | Q35116144 | ||
| Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype | Q35144377 | ||
| New insights into the pathogenesis of systemic sclerosis | Q35171981 | ||
| Assessment of disease severity and prognosis. | Q35188041 | ||
| Early T cell activation in the skin from patients with systemic sclerosis | Q35555856 | ||
| Vascular involvement in systemic sclerosis (scleroderma). | Q35557424 | ||
| T cell subsets and their signature cytokines in autoimmune and inflammatory diseases | Q35558638 | ||
| Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis | Q35588318 | ||
| Systemic sclerosis: a prototypic multisystem fibrotic disorder | Q35649427 | ||
| Pathogenesis of Systemic Sclerosis | Q35693212 | ||
| Is systemic sclerosis an antigen-driven T cell disease? | Q35799608 | ||
| Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease | Q35840797 | ||
| Fibrotic disease and the T(H)1/T(H)2 paradigm | Q35852270 | ||
| Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis | Q35958582 | ||
| Immunology of systemic sclerosis | Q36071751 | ||
| Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells | Q36342722 | ||
| Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis | Q36503865 | ||
| Update on pathophysiology of scleroderma with special reference to immunoinflammatory events | Q36761364 | ||
| Autoimmunity in systemic sclerosis: current concepts | Q36821512 | ||
| Recent advances on pathogenesis and therapies in systemic sclerosis | Q37026795 | ||
| The microvascular endothelium in scleroderma | Q37265791 | ||
| Vascular disease in scleroderma | Q37344793 | ||
| Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations | Q37453883 | ||
| How diverse--CD4 effector T cells and their functions | Q37502276 | ||
| Overview of pathogenesis of systemic sclerosis | Q37504301 | ||
| NK cell autoreactivity and autoimmune diseases. | Q37552129 | ||
| B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis | Q37690672 | ||
| Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts | Q37691158 | ||
| Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction | Q37691199 | ||
| Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis | Q37780326 | ||
| Fibrosis and immune dysregulation in systemic sclerosis | Q37791685 | ||
| Natural killer cells in human autoimmune diseases | Q37805560 | ||
| Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group | Q37809920 | ||
| T cells in systemic sclerosis: a reappraisal | Q38009282 | ||
| T cell abnormalities in systemic sclerosis with a focus on Th17 cells | Q38077615 | ||
| Systemic sclerosis: genetics and epigenetics | Q38082085 | ||
| Review: evidence that systemic sclerosis is a vascular disease | Q38105984 | ||
| The diagnosis and classification of mixed connective tissue disease | Q38181675 | ||
| The diagnosis and classification of undifferentiated connective tissue diseases | Q38187326 | ||
| Fibrosis--a lethal component of systemic sclerosis | Q38206104 | ||
| Interleukin-17 in human inflammatory diseases | Q38254127 | ||
| Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis | Q38325712 | ||
| Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee | Q39513167 | ||
| The role of TH17-associated cytokines in health and disease. | Q39592419 | ||
| Autoantibodies in systemic sclerosis | Q39726030 | ||
| Rituximab for refractory digital infarcts and ulcers in systemic sclerosis | Q40183904 | ||
| Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease. | Q41223874 | ||
| Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients | Q41713934 | ||
| Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. | Q42637683 | ||
| Lymphocyte phenotypes in systemic sclerosis | Q43053169 | ||
| Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. | Q43776928 | ||
| Cellular infiltrates in scleroderma skin | Q44017889 | ||
| Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis | Q44514354 | ||
| Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. | Q44939473 | ||
| Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? | Q45715684 | ||
| Th1, Th2, Th17, and regulatory cytokines in children with different clinical forms of allergy. | Q46152695 | ||
| Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement | Q46474228 | ||
| Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. | Q46721469 | ||
| Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells | Q47368380 | ||
| Association of killer cell immunoglobulin-like receptors with scleroderma | Q47596821 | ||
| Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis | Q48003008 | ||
| Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. | Q48008700 | ||
| Lack of natural killer cell augmentation in vitro by human interferon gamma in a subset of patients with systemic sclerosis. | Q51020910 | ||
| CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. | Q52014063 | ||
| CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis. | Q52058629 | ||
| Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). | Q52119725 | ||
| Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. | Q54014748 | ||
| 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. | Q54164380 | ||
| Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
| Scleroderma | Q54165664 | ||
| GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. | Q54367655 | ||
| Activation-Induced Expression of CD56 by T Cells Is Associated With a Reprogramming of Cytolytic Activity and Cytokine Secretion Profile In Vitro | Q58143517 | ||
| Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl | Q58160729 | ||
| Immunophenotypic Characterization of Normal Blood CD56+lo Versus CD56+hi NK-Cell Subsets and Its Impact on the Understanding of Their Tissue Distribution and Functional Properties☆ | Q60429946 | ||
| Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis | Q60810889 | ||
| Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis | Q62748342 | ||
| Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis | Q63283070 | ||
| Sequential dermal microvascular and perivascular changes in the development of scleroderma | Q68034596 | ||
| Scleroderma (systemic sclerosis): classification, subsets and pathogenesis | Q68330753 | ||
| Soluble and cellular markers of immune activation in patients with systemic sclerosis | Q68346501 | ||
| Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation | Q68428238 | ||
| Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations | Q70360845 | ||
| Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization | Q70387465 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 347-369 | |
| P577 | publication date | 2015-10-07 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review | |
| P478 | volume | 49 |
| Q30248983 | Autoimmunity in 2015. |
| Q40101148 | CD56 in the Immune System: More Than a Marker for Cytotoxicity? |
| Q64889589 | Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment. |
| Q92689696 | Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome |
| Q61805133 | Gene Profile Implication in Systemic Sclerosis Patients from Mexico |
| Q38781384 | Human CD56bright NK Cells: An Update |
| Q47245797 | Increased expression and modulated regulatory activity of co-inhibitory receptors PD-1, TIGIT and TIM-3 in lymphocytes of systemic sclerosis patients |
| Q50640109 | Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. |
| Q90726018 | Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release |
| Q50230077 | Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. |
Search more.